MAPK3 and melanoma: The ability of citral to interfere with cell survival-related signaling pathways was proven by revealing the lack of nuclear translocation of the extracellular signal-regulated kinase 1/2 (ERK1/2) and reduced expression of phosphatidylinositol 3-kinase (PI3K) and Akt in the citral-treated melanoma cells.